Search
Search Funnelback University
- Refined by:
- Date: Past month
Did you mean economiespast |u:www.enterprise.cam.ac.uk?
Your query has been expanded to Economics test |u:www.enterprize.cam.ac.uk. Search for Economics test |u:www.enterprise.cam.ac.uk instead.
1 -
10 of
36
search results for Economics test |u:www.enterprise.cam.ac.uk or Economics test |u:www.enterprize.cam.ac.uk
where 2
match all words and 34
match some words.
Fully-matching results
-
Spin-out PredictImmune wins £4.3m from Wellcome to evaluate its…
https://www.enterprise.cam.ac.uk/news/spin-predictimmune-wins-4-3m-wellcome-evaluate-prognostic-test/22 Feb 2023: Spin-out PredictImmune wins £4.3m from Wellcome to evaluate its prognostic test. ... Published studies indicate that there are likely to be significant clinical and economic benefits in the use of biomarker tests to guide first line treatment based on -
Cambridge Enterprise invests in PredictImmune – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-invests-in-predictimmune/22 Feb 2023: PredictImmune has carried out considerable market research into the medical need for the tests and the health economic benefits that they will deliver. ... Tags:Image: Test tubes. Stay in touch with the latest updates from Cambridge Enterprise. Results that match 1 of 2 words
-
The economic impact of the University of Cambridge – Cambridge…
https://www.enterprise.cam.ac.uk/news/the-economic-impact-of-the-university-of-cambridge/21 Mar 2023: London Economics, one of Europe’s leading specialist economics and policy consultancies, was commissioned to assess the University’s economic impact through a range of activities. ... This report by London Economics is a comprehensive attempt to -
New prognostic test could enable personalised treatment of IBD –…
https://www.enterprise.cam.ac.uk/news/new-prognostic-test-could-enable-personalised-treatment-of-ibd/22 Feb 2023: useful, scaleable test by looking at whole blood samples in conjunction with CD8 T-cells and using widely-available technology. ... They found the new test was 90-100% accurate in correctly identifying patients who did not require multiple treatments. -
Cambridge researcher gets green light for while-you-wait Hep B test – …
https://www.enterprise.cam.ac.uk/news/cambridge-researcher-gets-green-light-for-while-you-wait-hep-b-test/22 Feb 2023: Cambridge researcher gets green light for while-you-wait Hep B test. Share:. ... Other tests in the pipeline include rapid tests for the detection of HIV and influenza. -
Oxford-Cambridge-joint-investor-event
https://www.enterprise.cam.ac.uk/news/oxbridge-research-city-investors/22 Feb 2023: greatest societal and economic benefit from that world beating research. ... greatest societal and economic benefit from that world beating research.”. -
Cambridge spin-out PredictImmune announces new US patent – Cambridge…
https://www.enterprise.cam.ac.uk/news/spin-predictimmune-announces-new-us-patent/22 Feb 2023: The focus of the US patent is on the biological mechanism of the test, which demonstrates whether a patient does or does not exhibit T cell exhaustion. ... tests in these devastating and chronic diseases and further enables our US commercial strategy. -
Sphere Fluidics wins award for academic spin-outs – Cambridge…
https://www.enterprise.cam.ac.uk/news/sphere-fluidics-wins-award-for-academic-spin-outs/23 Feb 2023: billions of miniaturised tests in tiny picodroplets. ... Among other things, the technology allows tests on individual cells as well as whole “libraries” of cells. -
Cambridge Enterprise joins £2.4 million funding for Cytora –…
https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-joins-2-4-million-funding-for-cytora/22 Feb 2023: The business, which spun out of the University of Cambridge, is focused on capturing hidden economic insights that exist in online data, giving clients a comprehensive overview of what is changing -
Cambridge Enterprise announces 2010 results – Cambridge Enterprise
https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-announces-2010-results/23 Feb 2023: This year, the Fund made seed investments in two new Cambridge spin-outs: Sphere Fluidics, which is developing droplets that serve as ‘miniature test tubes’, and PneumaCare, which has developed a
Refine your results
clear all
Date
Search history
Recently clicked results
Recently clicked results
Your click history is empty.
Recent searches
Recent searches
Your search history is empty.